In evaluating patient disposition, the large proportion of hemophilia A patients excluded from Objective 1—170/274 (62%) in the JMDC population and 803/1266 (63%) in the MDV population—indicates that the majority of hemophilia A patients are not receiving continuous prescriptions of FVIII replacement as defined in our study. The gene discussed is F8; the disease is hemophilia A.